Immunoexpression of Transforming Growth Factor Beta 3 (TGFß3) and Its Receptor Type III (TGFßRIII) in Basal Cell Carcinomas.
Curr Health Sci J
; 44(2): 166-171, 2018.
Article
en En
| MEDLINE
| ID: mdl-30746165
Basal cell carcinomas (BCCs) are malignant tumors with particular biological prognosis and behavior, and the biomolecular investigation of these lesions can provide important therapeutic targets for epithelial neoplasia. In this study we analyzed the immunoexpression of transforming growth factor beta 3 (TGFß3) and its receptor type III (TGFßRIII) for 53 cases of BCC in relation to the main histopathological prognostic parameters. The results indicated statistically significant differences of TGFß3 and TGFßRIII expression related to histological type and lesion stage, the both proteins being higher expressed in adenoid and morpheaform advanced stage tumors. In this study, TGFß3 and TGFßRIII immunoexpression analysis indicated their utility for identifying aggressive BCCs with potential for tumor progression.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Curr Health Sci J
Año:
2018
Tipo del documento:
Article
País de afiliación:
Rumanía
Pais de publicación:
Rumanía